WHO WE ARE ?
CVasThera was founded in 2016 by highly experienced pharmaceutical industry professionals, with a world-class track record of CV drug discovery, drug development, clinical trials, and company management. We are experienced professionals in pre-clinical and clinical development who know that there is a better way to develop drugs.
Our team
"Our business model for an optimal development program is based on 4 keys"
Intellectual property strategy «Patent»
Patent protection for pharmaceutical products in the developing world can help to encourage the development of new medicines for diseases that affect these countries, by providing protection for the investments that need to be made by the pharmaceutical companies. Pharmaceutical companies often maintain that patent protection for drugs ensures that they are able to invest billions of dollars into the development of new products, by making sure that they will be able to take advantage of the sales. Based on long experiences , CVasThera was dedicated to assure the innovation of new proposal patents.
Access to appropriate Expertise scientific
New identified compound or target molecule is of high interest, but it is often just a first step in a long process that will determine the potential of this compound or a related congener to be developed into an authority-approved drug. Many of the early clincial trials are performed with a drug known to work safely in one indication, to support a new label expansion but integrative physiology and/or pharmacology is oftenly bypassed. Integrate biological, chemical and pharmacological data to help drive innovation and support earlier decision-making when developing new hypotheses around targets, drugs, and how to translate animal models into humans is our area of expertise.
Access to appropriate funding
While basic discovery research is funded primarily by government and by philanthropic organizations, early-stage development is funded mainly by pharmaceutical companies or venture capitalists. At CVasThera, we are dedicated to accelerating innovation and advancing science at early-stage development. That’s why we want to foster independent research by reducing financial hurdles for researchers.
Access to fast timelines to clinical proof of concept
Proof-Of-Concept (POC) is a pivotal milestone in the drug development process. In front of the failure number, the early development processes must be re-engineered to improve R&D productivity and shorten project timelines, whilst at the same time allowing a more flexible and interrogative investigation of a drug candidates unique potential. Based on long experiences , CVasThera was dedicated to evaluating integrated and adaptive clinical protocols combining healthy volunteer and POC investigations.
Intellectual property strategy «Patent»
Patent protection for pharmaceutical products in the developing world can help to encourage the development of new medicines for diseases that affect these countries, by providing protection for the investments that need to be made by the pharmaceutical companies. Pharmaceutical companies often maintain that patent protection for drugs ensures that they are able to invest billions of dollars into the development of new products, by making sure that they will be able to take advantage of the sales. Based on long experiences , CVasThera was dedicated to assure the innovation of new proposal patents.
Access to appropriate Expertise scientific
New identified compound or target molecule is of high interest, but it is often just a first step in a long process that will determine the potential of this compound or a related congener to be developed into an authority-approved drug. Many of the early clincial trials are performed with a drug known to work safely in one indication, to support a new label expansion but integrative physiology and/or pharmacology is oftenly bypassed. Integrate biological, chemical and pharmacological data to help drive innovation and support earlier decision-making when developing new hypotheses around targets, drugs, and how to translate animal models into humans is our area of expertise.
What we do ? & How we work
PORTFOLIO
The expertise of CVasThera is engaged in promising projects.
-
BOS1728515 for the treatment of atrial fibrillationExpertise and analyses for Boston Pharma’s project.
-
OP2113 for the treatment of acute myocardial infarctionExpertise and CSO position for OP2 drugs project
-
CVT12011965 for the treatment of Crohn's diseaseProject leads by CvasThera, a new target to treat crisis, prevent relapses, and pain.
